NCT05285384已完成不适用
An Open-Label, Single-Arm Clinical Trial to Evaluate the Immunogenicity and Safety of a Booster Dose of an Adjuvanted Recombinant Spike Protein COVID-19 Vaccine (SpikoGen) in Kidney Transplant Recipients After Two Doses of Sinopharm COVID-19 Vaccine
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Cinnagen
- 入组人数
- 43
- 试验地点
- 1
- 主要终点
- Percentage of participants with seroconversion for S1 binding IgG antibodies
研究概览
简要总结
This is an open-label, single-arm clinical trial designed to evaluate the immunogenicity and safety of a booster dose of an adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine (SpikoGen) produced by CinnaGen Co. in kidney transplant recipients after two doses of Sinopharm's inactivated virus vaccine. A total of 100 adult individuals receive a single dose of the SpikoGen COVID-19 vaccine at 1 to 3 months after the second dose of the Sinopharm COVID-19 vaccine. The injection is given in the deltoid muscle of the non-dominant arm. For immunogenicity assessments, blood samples will be collected one month after the booster injection. For safety assessments, all participants will be followed up for one month.
Study hypotheses include:
- A booster dose of the SpikoGen COVID-19 vaccine induces strong immunogenicity against SARS-CoV-2 in adult kidney transplant recipients who were fully vaccinated with Sinopharm COVID-19 vaccine.
- A booster dose of the SpikoGen COVID-19 vaccine is safe and tolerable in adult kidney transplant recipients who were fully vaccinated with Sinopharm COVID-19 vaccine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female ≥18 years
- •Willing and able to comply with all study requirements, including scheduled visits, intervention, and laboratory tests
- •Kidney transplant recipients who had received two doses of Sinopharm vaccine after transplantation
- •Females must not be pregnant or breastfeeding
- •At least six months should have passed from the time of transplantation
- •Between 1 to 3 months should have passed from the second dose of Sinopharm vaccine
排除标准
- •Subjects with signs of active SARS-CoV-2 infection at the screening visit
- •Subjects with a history of SARS-CoV-2 infection based on a positive PCR test result after the second dose of the primary vaccination
- •Subjects with an active CMV infection that requires treatment
- •Subjects who have received rituximab within 6 months prior to the screening visit
- •Subjects who have received intravenous immune globulin (IVIG) within 6 months prior to the screening visit
- •Subjects who have a history of severe allergic reactions (e.g., anaphylaxis) to the study vaccine, any components of the study interventions, or any pharmaceutical products.
- •Subjects who have received any other investigational products within 30 days prior to the screening visit or intend to participate in any other clinical studies during the period of this study.
- •Subjects who have experienced transplant rejection within 30 days prior to the screening visit
- •Subjects with any condition that may increase the risk of participating in the study or may interfere with the evaluation of the primary endpoints of the study in the investigator's opinion.
结局指标
主要结局
Percentage of participants with seroconversion for S1 binding IgG antibodies
时间窗: One month after the booster dose
As measured by ELISA
Percentage of participants with seroconversion for SARS-CoV-2 neutralizing antibodies
时间窗: One month after the booster dose
As measured by ELISA
次要结局
- Geometric mean fold rise (GMFR) for SARS-CoV-2 neutralizing antibodies in subjects either with or without antibody responses at baseline(One month after the booster dose)
- Incidence of unsolicited adverse events(For one month after the booster dose)
- Change in T-cell IFN-γ secretion from baseline to one month after the booster dose(Baseline and one month after the booster dose)
- Incidence of solicited adverse events(For 7 days after the booster dose)
- Geometric mean fold rise (GMFR) for S1 binding IgG antibodies(One month after the booster dose)
- Geometric mean fold rise (GMFR) for S1 binding IgG antibodies in subjects either with or without antibody responses at baseline(One month after the booster dose)
- Percentage of participants with seroconversion for S1 binding IgG antibodies in subjects either with or without antibody responses at baseline(One month after the booster dose)
- Geometric mean fold rise (GMFR) for SARS-CoV-2 neutralizing antibodies(One month after the booster dose)
- Percentage of participants with seroconversion for SARS-CoV-2 neutralizing antibodies in subjects either with or without antibody responses at baseline(One month after the booster dose)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
The Immunogenicity and Safety of V-01-351/V-01D Bivalence VaccineCOVID-19 PandemicNCT05273528Livzon Pharmaceutical Group Inc.20
Unknown
早期 1 期
IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver CancerAdvanced Primary Liver CancerNCT05411757Shandong Public Health Clinical Center12
Unknown
不适用
A Prospective, Open-label, Single-arm Clinical StudyRecurrent Glioblastoma MultiformeNCT04689087Sun Yat-sen University40
招募中
1 期
U87 CAR-T in Patients With Advanced Head and Neck TumorsNasopharynx CancerHead and Neck CancerNCT06614686Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd20
招募中
2 期
Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative ResectionCarcinoma, HepatocellularNCT06454578Qilu Hospital of Shandong University30